In PNET, clinical studies have indicated a correlation between high survivin expression levels and a poor survival prognosis; patients with 5%, 5–50%, and > 50% positive nuclei had a median survival of 225, 101, and 47 months, respectively 21, 22. Here, BIRC5 is linked to primitive neuroectodermal tumor.